VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) (OTC:PMBHF), the University of Calgary (“UC”), and Heroic Hearts Canada (“HHC”, and collectively, the “Parties”) are pleased to announce that they have completed a Letter of Intent (“LOI”), and received initial Ethics Board Approval, to initiate an Observational Trial (the “Trial”) on patients treated with 3,4 Methylenedioxymethamphetamine (“MDMA”) through Health Canada’s Special Access Program (SAP). The Parties will each play an important role in the execution of this trial:

• PharmAla Biotech is currently the only manufacturer of GMP MDMA for clinical use in Canada. PharmAla will provide drug product to physicians under SAP through its licensed distribution partners, and connect clinicians and patients with UC researchers for voluntary data collection.
• The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances. The University of Calgary will have full rights to publication of data generated by the trial, with no limitation by the Parties.
• Heroic Hearts Project Canada, a charity supporting veteran mental health by facilitating access to psychedelic-assisted therapy, will offer its future program participants who receive MDMA-assisted therapy via the SAP the option to participate in the Trial and thereby contribute RWE.

The announcement of the Trial comes following the release yesterday of the Senate of Canada’s Subcommittee on Veterans report, The Time is Now: Granting equitable access to psychedelic-assisted therapies, which urged Veterans Affairs Canada to increase research into the treatment of veterans’ “moral injuries” such as Post-Traumatic Stress Disorder with psychedelic molecules, including MDMA. This trial will generate Real World Evidence (“RWE”) on the efficacy of MDMA in the treatment of Post-Traumatic Stress Disorder which may be submitted to Health regulators, including Health Canada and Veterans Affairs Canada. The Parties hope that data collected in the Trial will add to the knowledge base of both regulators and the scientific community on the real-world evidence of efficacy and safety of these treatments.

The Parties’ initial submission to the Review Ethics Board has been approved, and the parties intend to proceed to data gathering immediately. Subsequent Ethics Review Board submissions are contemplated in the LOI. As the trial is Observational in nature, no patients will be dosed as part of the trial’s protocol. The goal of the trial is to gather data on the efficacy of treatment for patients who are already qualified for treatment under the Special Access Program.

Quotes:

“Our ability to treat patients through SAP, while imperfect, remains a credit to Canadian regulators and an incredibly valuable tool for the collection of evidence of MDMA’s efficacy in real-world clinical outcomes. We’re incredibly pleased to work with Dr. Mayo and Heroic Hearts to bring together patients, clinicians, and scientists,” said Nick Kadysh, CEO, PharmAla Biotech. “We are already seeing amazing results in patients, and we believe we are currently the only company in the world that can generate evidence from SAP which can be shared directly with regulators, as well as the scientific community.”

“While clinical evidence in the form of trial data on the efficacy of MDMA as a treatment for PTSD has been published – and is encouraging – this is a global first: an assessment of the efficacy of MDMA in treating PTSD outside the bounds of a clinical trial,” said Dr. Leah Mayo, Parker Psychedelics Research Chair, University of Calgary. “This observational trial is only possible due to the unique partnership of the 3 groups represented here, and the data gathered should significantly add to the body of knowledge around MDMA-assisted therapies.”

“Heroic Hearts Canada is committed to making MDMA-assisted therapy and other innovative psychedelic-assisted therapies accessible to veterans, who experience disproportionately high rates of trauma and mental illness after service,” said David Fascinato, Executive Director, Heroic Hearts Canada. “This partnership is an important opportunity to add to the body of knowledge and support Health Canada and stakeholders such as Veterans Affairs Canada, in understanding the potential of MDMA-assisted therapy, with the goal of eventual approval so that it is accessible to all in need through approved healthcare channels.”

For more information, please visit www.PharmAla.ca, where you can sign up to receive regular new updates.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is the first publicly-traded company to manufacture clinical-grade MDMA. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla’s lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 1-855-444-6362
Website: www.PharmAla.ca

About the University of Calgary

UCalgary is Canada’s entrepreneurial university, located in Canada’s most enterprising city. It is a top research university and one of the highest-ranked universities of its age. Founded in 1966, its 35,000 students experience an innovative learning environment, made rich by research, hands-on experiences and entrepreneurial thinking. It is Canada’s leader in the creation of start-ups.

For more information, please contact:

For more information, visit ucalgary.ca. Stay up to date with UCalgary news headlines on Twitter @UCalgary. For access to UCalgary news releases, images and b-roll, and details on faculties and how to reach experts, check out our newsroom at ucalgary.ca/newsroom.
Media inquiries can be sent to Senior Communications Specialist Kelly Johnston This email address is being protected from spambots. You need JavaScript enabled to view it. and research inquiries can be directed to the Psychedelic and Cannabinoid Therapeutics Lab Research Coordinator, Kaitlin O’Grady (This email address is being protected from spambots. You need JavaScript enabled to view it.)

About Heroic Hearts Canada

Heroic Hearts Canada is a registered Canadian charity whose sole purpose is to empower veterans on their healing journey by connecting them with safe, effective, and transformative psychedelic-assisted therapies in Canada and abroad. Our programs facilitate access to vetted clinics providing psychedelic-assisted therapies and contribute to the growing base of evidence and research on the impacts of psychedelic-assisted therapies in Canada and abroad.

For more information, please contact:
David Fascinato
Executive Director
Heroic Hearts Canada
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.heroicheartsproject.ca

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com. 

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction